Vertex Targets Kalydeco as Incivek Sales Continue Swoon
By Marie Powers
Wednesday, January 30, 2013
After Tuesday's market close, Vertex Pharmaceuticals Inc. reported 2012 revenues of $1.53 billion, including net product revenues of $1.16 billion from Incivek (telaprevir) and $171.6 million from Kalydeco (ivacaftor), launched in the U.S. in February 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.